20 articles
Combining CD38 and PD-1 inhibitors produced durable remissions in relapsed NK/T-cell lymphoma, with median response duration exceeding 29 months.
Phase 1 data from 15 heavily pretreated Japanese myeloma patients confirms talquetamab's safety and efficacy, matching global trial results.
The BEGONIA trial finds durvalumab combined with trastuzumab deruxtecan achieves 62% response rate in hard-to-treat metastatic breast cancer.
A phase 1 trial finds intraventricular nivolumab is safe for leptomeningeal metastases, with median survival of 6.6 months.
Groundbreaking study shows PD-1 blockade achieves complete tumor elimination in most mismatch repair-deficient cancers, avoiding surgery.
A phase 3 trial finds scheduling immunochemotherapy before 3 PM nearly doubles progression-free and overall survival in NSCLC patients.
New research reveals how a specific protein causes anemia in myelodysplastic syndromes and predicts treatment response.
A randomized trial shows hydroxychloroquine and everolimus can dramatically reduce dormant tumor cells in breast cancer survivors, potentially preventing relapse.
New study shows circulating tumor cells can predict treatment response and reveal drug resistance patterns.
A new 'induce-target-kill' strategy uses TROP2-directed ADCs to eliminate drug-tolerant persister cells in EGFR-mutant lung cancer.
The ICARUS-LUNG01 trial sheds light on why some lung cancer patients respond to antibody-drug conjugates while others resist.
A phase 2 trial of datopotamab deruxtecan in 100 NSCLC patients reveals a 26% response rate and critical resistance biomarkers.
New research reveals how brain barrier variations affect cancer treatment delivery, potentially improving outcomes.
A prospective cohort study shows combining ctDNA with PSA levels dramatically improves survival prediction in high-volume metastatic prostate cancer patients.
New research identifies CRTAM protein as key target to prevent immune therapy toxicity while preserving cancer-fighting power.
Real-world study of 664 patients reveals effective treatment options after T-DXd discontinuation, with low lung disease recurrence rates.
Revolutionary blood tests can detect breast cancer changes in real-time without invasive tissue biopsies.
ROME trial shows liquid biopsies can effectively guide personalized cancer therapy, potentially replacing invasive tissue biopsies.
New consensus on genetic testing for cancer drugs creates fresh questions about finding the right dose for each patient.
A triple immunotherapy unlocks anti-tumor CD4+ T cells — not CD8+ — to clear pancreatic tumors in mice, reshaping the immunotherapy playbook.
